Abstract
The mechanism of elite control of HIV-1 replication is not fully understood. While immunosuppression due to rituximab based chemotherapy has been associated with increased replication of HBV, CMV, and HIV-1, control of replication-competent HIV-1 was maintained in an elite controller/suppressor treated with a regimen that included vincristine, cyclophosphamide, prednisone, four rounds of plasmapheresis and ten cycles of rituximab. The data suggests that de-novo antibody responses do not play a significant role in the control of viral replication in these patients.
Copyright © 2011 Elsevier B.V. All rights reserved.
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage*
-
Drug Therapy / methods
-
HIV Infections / drug therapy*
-
HIV Infections / immunology
-
HIV Infections / virology*
-
HIV-1 / classification*
-
HIV-1 / immunology
-
HIV-1 / isolation & purification*
-
Humans
-
Immunosuppressive Agents / administration & dosage*
-
Male
-
Middle Aged
-
Molecular Sequence Data
-
Neoplasms / complications
-
Neoplasms / drug therapy
-
Rituximab
-
Sequence Analysis, DNA
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Immunosuppressive Agents
-
Rituximab
Associated data
-
GENBANK/HQ846896
-
GENBANK/HQ846897
-
GENBANK/HQ846898
-
GENBANK/HQ846899
-
GENBANK/HQ846900
-
GENBANK/HQ846901
-
GENBANK/HQ846902
-
GENBANK/HQ846903
-
GENBANK/HQ846904
-
GENBANK/HQ846905
-
GENBANK/HQ846906
-
GENBANK/HQ846907
-
GENBANK/HQ846908
-
GENBANK/HQ846909
-
GENBANK/HQ846910
-
GENBANK/HQ846911
-
GENBANK/HQ846912
-
GENBANK/HQ846913
-
GENBANK/HQ846914
-
GENBANK/HQ846915